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ABSTRACT We tested whether severe congestive heart
failure (CHF), a condition associated with excess free-water
retention, is accompanied by altered regulation of the vaso-
pressin-regulated water channel, aquaporin-2 (AQP2), in the
renal collecting duct. CHF was induced by left coronary artery
ligation. Compared with sham-operated animals, rats with
CHF had severe heart failure with elevated left ventricular
end-diastolic pressures (LVEDP): 26.9 6 3.4 vs. 4.1 6 0.3
mmHg, and reduced plasma sodium concentrations (142.2 6
1.6 vs. 149.1 6 1.1 mEqyliter). Quantitative immunoblotting
of total kidney membrane fractions revealed a significant
increase in AQP2 expression in animals with CHF (2676 53%,
n 5 12) relative to sham-operated controls (100 6 13%, n 5
14). In contrast, immunoblotting demonstrated a lack of an
increase in expression of AQP1 and AQP3 water channel
expression, indicating that the effect on AQP2 was selective.
Furthermore, postinfarction animals without LVEDP eleva-
tion or plasma Na reduction showed no increase in AQP2
expression (121 6 28% of sham levels, n 5 6). Immunocyto-
chemistry and immunoelectron microscopy demonstrated
very abundant labeling of the apical plasma membrane and
relatively little labeling of intracellular vesicles in collecting
duct cells from rats with severe CHF, consistent with en-
hanced trafficking of AQP2 to the apical plasma membrane.
The selective increase in AQP2 expression and enhanced
plasma membrane targeting provide an explanation for the
development of water retention and hyponatremia in severe
CHF.
Severe heart failure is generally associated with marked de-
fects in renal handling of sodium and water resulting in
extracellular fluid expansion and hyponatremia. The renal
water retention is thought to be mediated in part by increased
baroreceptor-mediated vasopressin release (for a recent re-
view, see ref. 1). Vasopressin binds to V2 receptors in the
basolateral plasma membrane in kidney collecting duct prin-
cipal cells. V2 receptors activate adenylyl cyclase through
heterotrimeric–GTP binding proteins, increasing cAMP levels
which in turn increase water reabsorption. Increased water
reabsorption presumably contributes to the development of
hyponatremia. However, the renal mechanisms involved in the
increased water reabsorption are poorly defined. The present
study is aimed at analyzing the role of renal aquaporins (AQPs)
in the development of renal water retention in congestive heart
failure (CHF).
The AQPs are a family of membrane water channels that
mediate rapid water transport across cell membranes (2).
AQP2 (3) was found to be the predominant vasopressin-
regulated water channel of the kidney collecting duct (for
recent reviews, see refs. 4 and 5). In principal cells of the
collecting duct, AQP2 is localized in the apical plasma mem-
brane and in cytoplasmic vesicles (6). Water reabsorption in
the collecting duct is regulated both by short-term and long-
term mechanisms, both of which have been shown to depend
critically on AQP2. Short-term regulation occurs as a result of
exocytic insertion of AQP2 water channels into the apical
plasma membrane in response to vasopressin (7–10). In addi-
tion, long-term regulation of AQP2 expression has recently
been shown to play a major role for regulation of collecting
duct water reabsorption. It has been shown that thirsting or
water loading for 24 hr or more produces marked changes in
AQP2 expression in collecting duct principal cells (6). More-
over, chronic vasopressin infusion in Brattleboro rats, which
manifest central diabetes insipidus due to a defect in the
neurophysinyvasopressin gene, induces a substantial increase
in AQP2 expression (11). This increase in AQP2 is paralleled
by a comparable increase in osmotic water permeability (11),
demonstrating a direct role of vasopressin in the long-term
regulation of AQP2.
It has been recently demonstrated that defective long-term
regulation of AQP2 plays a key role in several water balance
disorders. Thus, it has been shown that down-regulation of
AQP2 in response to lithium treatment, hypokalemia or
release of ureteral obstruction, is associated with development
of polyuria in proportion to the decrease in AQP2 (12–14).
Therefore, down-regulation of AQP2 appears to be a general
mechanism in the development of commonly acquired forms
of nephrogenic diabetes insipidus. Recently it has also been
shown that kidneys of rats with CCl4-induced liver cirrhosis
and acites have an increased expression of AQP2 (15). This
suggests that AQP2 also has a role in the development of water
retention. In the present study we demonstrate that defective
short- and long-term regulation of AQP2 are associated with
severe CHF.
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METHODS
Experimental Animals. Wistar rats (Møllegard Breeding
Centre, Eiby, Denmark) were a fed commercial rat chow (no.
1310; Altromin, Lage, Germany) and were allowed free access
to water.
Surgical Preparation. Rats were anaesthetized in an inha-
lation chamber with 4% halothane in 1:1 N2OyO2 gas mixture.
After insertion of an endotracheal tube the animal was arti-
ficially ventilated with 1% halothane in a 1:1 N2OyO2 gas
mixture. Tidal volume and respiratory rate were adjusted to
maintain arterial pH between 7.35 and 7.45. During surgery
the animal was placed on a heated table that maintained rectal
temperature at 37–388C. Left coronary artery ligation, used to
produce CHF (16–18), was performed via a parasternal tho-
racotomy and a 6-0 silk suture was placed between the
pulmonary trunk and the left auricle. Sham-operation was
performed without ligating the left coronary artery. To min-
imize postsurgical pain, rats were treated postoperatively with
buprenorphine 0.2 mgykg s.c. (Anorfin, Bie & Berntsen,
Rødovre, Denmark) for 2 days. Two weeks after heart surgery
permanent Tygon catheters (Bie & Berntsen) were inserted
into the femoral artery and vein. To prevent coagulation,
catheters were filled with 50% dextrose with 1,000 units
heparinyml and 10,000 units streptokinaseyml.
Experimental Protocol. Physiological examinations were
performed 3 weeks after heart surgery since the functional
deterioration after left coronary artery ligation is generally
maximal at this time (16, 17). Measurements of arterial
pressure were performed in the conscious, unrestrained state
in the rats home cage. The arterial catheter was connected via
a swivel system to a Baxter Uniflow transducer and mean
arterial pressure was displayed continuously on a Grass model
7D polygraph. After a 2-hr recording period, a 300-ml arterial
blood sample was drawn for measurements of plasma sodium
and potassium. The rat was then anaesthetized with halothane
in 1:1 N2OyO2, incubated and artificially ventilated, and a
Tygon catheter was inserted into the left ventricle via the right
carotid artery for measurement of left ventricular end-diastolic
pressure (LVEDP). Accurate measurement of LVEDP was
performed by adjusting the concentration of halothane to
maintain after-load during anaesthesia at the same level as
mean arterial pressure recorded in the conscious state.
Membrane Fractionation for Immunoblotting. The kidneys
were homogenized (0.3 M sucrosey25 mM imidazoley1 mM
EDTA, pH 7.2y8.5 mM leupeptiny1 mM phenylmethylsulfonyl
f luoride) and the homogenate was centrifuged in a Beckman
L8M centrifuge at 4,000 3 g for 15 min. The supernatant was
then centrifuged at 200,000 3 g for 1 hr to produce a pellet
containing both plasma membrane and intracellular vesicle
fractions (8, 12). Gel samples were prepared using Laemmli
sample buffer containing 2% SDS.
Electrophoresis and Immunoblotting. Samples of mem-
brane fractions from total kidney (20 mgylane) were run on
12% polyacrylamide minigels (Bio-Rad Mini Protean II). For
each gel an identical gel was run in parallel and subjected to
Coomassie staining to assure identical loading (19). The other
gel was subjected to immunoblotting. Blots were blocked with
5% milk in PBS-T (80 mM Na2HPO4y20 mM NaH2PO4y100
mMNaCly0.1%Tween 20, pH 7.5) for 1 hr, and incubated with
affinity purified anti-AQP2 [40 ng IgGyml IgG (6–8, 11)] or
with AQP1 immune serum [diluted 1:2000; generously pro-
vided by Peter Agre (20)], or with affinity purified anti-AQP3
[0.5 mgyml (21)]. The labeling was visualized with horseradish
peroxidase-conjugated secondary antibody (P448; Dako; di-
luted 1:3,000) using enhanced chemiluminescence system
(Amersham). Controls were made with replacement of pri-
mary antibody with antibody pre-absorbed with immunizing
peptide IgG), or with nonimmune IgG.
Quantitation of AQP2, AQP1, and AQP3 Expression. ECL
films with bands within the linear ranged were scanned (8)
using a Hewlett–Packard Scanjet scanner. For AQP2 and
AQP1 both the 29-kDa and the 35- to 50-kDa band [corre-
sponding to nonglycosylated and the glycosylated species (22)]
were scanned as described (12–14, 19). For AQP3, the 27-kDa
and the 33- to 40-kDa bands (corresponding to nonglycosy-
lated and the glycosylated species) were scanned as described
(19, 21). The labeling density was quantitated (12, 13) of blots
where samples from CHF kidneys were run on each gel with
control kidneys from sham-operated animals. AQP labeling in
the samples from the experimental animals was calculated as
a fraction of the mean sham control value for that gel.
Comparisons between groups were made by unpaired t test. P
values , 0.05 were considered significant.
Preparation of Tissue for Immunocytochemistry. The kid-
neys from additional four CHF animals and four sham animals
were fixed with 4% paraformaldehyde in 0.1 M Na cacodylate
buffer, pH 7.4 (6, 11, 20). Tissue blocks were infiltrated for 30
min with 2.3 M sucrose containing 2% paraformaldehyde,
mounted on holders, and rapidly frozen in liquid nitrogen (20).
For light microscopy, the frozen tissue blocks were cryosec-
tioned (0.8 mm, Reichert Ultracut S Cryoultramicrotome) and
sections were incubated with affinity purified anti-AQP2 an-
tibodies (LL127AP or LL358AP) and the labeling was visu-
alized with horseradish peroxidase-conjugated secondary an-
tibody (P448 1:100; Dako). For immunoelectron microscopy
frozen blocks were freeze-substituted and embedded in Lowi-
cryl HM20 (23) (Reichert automatic freeze substitution sys-
tem). Ultrathin Lowicryl HM20 sections (40–60 nm) were
incubated with affinity purified anti-AQP2 (LL127AP) and
the labeling was visualized with goat-anti-rabbit IgG conju-
gated to 10 nm colloidal gold particles (GAR.EM10; BioCell
Research Laboratories).
Table 1. Physiological and pathophysiological parameters in sham-operated animals (Sham) and rats with heart failure
(congested or compensated)
Sham
Heart failure
Congestive Compensated All
LVEDP, mm Hg 4.1 6 0.3 26.9 6 3.4* 7.2 6 3.9 20.3 6 2.8*
Serum Na1, mEqyliter 149.1 6 1.1 142.2 6 1.6* 146.5 6 1.3 143.8 6 1.4*
Heart weight, mg 787 6 16 1,005 6 54* 878 6 52 963 6 40*
Mean arterial pressure, mm Hg 102 6 2 95 6 4 100 6 2 97 6 3
Kidney weight, mg 897 6 22 938 6 34 869 6 35 915 6 22
Rat weight, g 227 6 5 223 6 6 232 6 2 226 6 4
Rats, n 14 12 6 18
The animals with heart failure were divided into two groups, one with CHF and one with compensated heart failure. The
group termed heart failure-all represent all animals that were subjected to left coronary artery ligation 4 weeks earlier—i.e.,
the two groups combined. Values are expressed as mean 6 SE.
*P , 0.05 when compared with the sham-operated group.
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RESULTS
Increase in LVEDP and Reduced Plasma Sodium Concen-
tration in Rats with Severe CHF. Three weeks after left
coronary artery ligation most rats developed a dramatic in-
crease in LVEDP, as described (16–18). Based on the char-
acterization of this model by others, rats with LVEDP . 15
mmHg were considered having severe CHF. As demonstrated
in Table 1, LVEDP was 4.16 0.3 mmHg in sham controls (n5
14) and was 26.9 6 3.4 in the group with high LVEDP (n 5
12). Importantly this group of rats also had a significant
reduction in plasma Na1 concentration from 149.1 6 1.1 to
142.26 1.2 mEqyliter. Thus, this group had CHF with reduced
plasma sodium concentration. The second group of rats with
infarction in absence of CHF were selected based on LVEDP
values lower than 15 mmHg (on average 7.2 6 3.9, n 5 6)
compatible with mild compensated heart failure. In contrast to
the group with high LVEDP plasma sodium concentrations
were unchanged in this group (Table 1).
Increase of AQP2 Expression in Rats with Severe CHF. As
previously shown, the affinity purified anti-AQP2 antibody
recognizes the 29-kDa and the 35- to 50-kDa band (Fig. 1; refs.
13 and 19), corresponding to nonglycosylated and glycosylated
AQP2 (22). The AQP2 bands were ablated by use of antibody
previously absorbed with immunizing peptide (Fig. 1B) as also
previously demonstrated (6, 11, 12). As shown in Fig. 1, a
FIG. 1. Immunoblots of membrane fractions (20 mgylane) from
total rat kidney prepared from sham-operated rats (S) and experi-
mental rats with CHF. (A) The immunoblot was reacted with affinity
purified anti-AQP2 and reveal 29-kDa and 35- to 50-kDa AQP2 bands.
A more prominent labeling is seen in CHF rat kidneys. (B) Immu-
noblotting control. (C) Densitometry performed on all sham-operated
animals (n 5 14) and all animals with severe CHF (n 5 12). A highly
significant increase in AQP2 expression is seen in CHF animals.
FIG. 2. Immunohistochemical localization of AQP-2 water chan-
nels in kidney inner medulla of rat kidney in sham-operated rats (A)
and rats with CHF (B). (A) Sham-operated controls. Abundant
labeling is seen exclusively in collecting duct principal cells. The
labeling is found scattered both in the plasma membrane domains
(arrow) and in cytoplasmic domains corresponding to intracellular
vesicles (arrowheads). (Inset) Immunolabeling control. (B) In rats with
CHF strong AQP2 labeling is associated with the apical plasma
membrane (arrows) and with the basolateral plasma membrane. In
contrast only little labeling of cytoplasmic vesicles is seen. (3840.)
Table 2. Expression of AQP2, AQP1, and AQP3 expressed as
percentage of the level in sham-operated animals (Sham)
Sham
Heart failure
Congestive Compensated All
AQP2 expression 100 6 13 267 6 53*† 121 6 28 218 6 41*
AQP1 expression 100 6 14 119 6 18 95 6 8 109 6 10
AQP3 expression 100 6 6 72 6 11* 112 6 8 93 6 8
Rats; n 14 12 6 18
The animals with heart failure were divided into two groups, one
with CHF and one with compensated heart failure, based on deter-
minations of LVEDP (see Table 1 and Methods). Heart failure-all
represent all animals that were subjected to left coronary artery
ligation 4 weeks earlier—i.e., the two groups combined. Values are
expressed as mean 6 SE.
*P , 0.05 when group was compared to sham.
†P , 0.05 when compared to the group with compensated heart
failure.
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significant increase of both the 29-kDa and the 35- to 55-kDa
AQP2 bands was observed in rats with CHF (Fig. 1A).
Densitometry of all samples from rats with CHF revealed a
marked increase in AQP2 expression from 1006 13% (n5 14)
in sham-operated controls to 267 6 53% (n 5 12). In contrast
no increase in AQP2 expression was noted in the group having
compensated heart failure (Table 2), indicating a role of
increased AQP2 expression for the development of increased
water retention (as indicated by the decrease in plasma sodium
concentration).
Immunocytochemical Observations. Kidneys from rats with
CHF (having LVEDP . 15 mmHg) were fixed and processed
for immunocytochemistry. AQP2 labeling was seen exclusively
in collecting duct principal cells (Fig. 2). There was a promi-
nent difference in the subcellular localization of AQP2 in
kidneys from CHF and sham-operated rats. In CHF rats,
AQP2 labeling was seen predominantly localized to the plasma
membrane domains with abundant labeling of the apical
plasma membrane and only marginal labeling of cytoplasmic
vesicles (Fig. 2B). In contrast, AQP2 labeling in kidneys of
sham-operated control animals showed a substantial labeling
of vesicles throughout the cytoplasm and less prominent
plasma membrane labeling (Fig. 2A). Some labeling was also
present in the basolateral plasma membranes, as previously
documented (6–8, 12).
Immunoelectron microscopy was used to examine if the
extensive labeling of AQP2 in the apical region of collecting
duct principal cells was associated with the plasma membrane
in rats with CHF. This was done to assure that the targeting of
AQP2 to the apical plasma membrane was intact in these
animals. Immunogold labeling revealed very strong labeling of
the apical plasma membrane (Fig. 3) and only little labeling
was associated with subapical vesicles (Fig. 3). Immunolabeling
controls were negative (data not shown).
AQP2 but Not AQP1 or AQP3 Expression Is Up-Regulated.
The expression of two other water channels AQP1 and AQP3
was examined. This was done to test if there is a selective up
regulation of AQP2 in CHF or a more general increase in
water channel expression to facilitate water reabsorption.
AQP1 (24, 25) is expressed in the proximal tubule and in
descending thin limbs of the loop of Henle (20) and the
expression of this water channel is not altered in response to
changes in body water balance (19). As shown in Fig. 4 A and
C, there is no increase in AQP1 expression in rats with CHF.
The expression is 100 6 14% (n 5 14) and 119 6 18% (n 5
12) in sham controls and in rats with CHF, respectively (Table
2). AQP3 (26–28) is expressed in the basolateral plasma
membrane of collecting duct principal cells (21). Quantitative
immunoblotting revealed no increase in AQP3 expression (Fig.
4 and Table 2). Indeed a modest decrease in expression was
noted in the same membrane fraction used in parallel to
examine AQP2 as well as AQP1 and AQP3 expression (Table
2). Thus, there is a selective increase in AQP2 expression
associated with CHF with no increase in AQP1 or AQP3
expression.
DISCUSSION
The present results demonstrate that severe CHF is associated
with marked dysregulation of the AQP2 water channel in the
renal collecting duct. Two modes of dysregulation were re-
vealed: (i) a marked increase in the abundance of AQP2 water
channel protein in the collecting duct principal cells, and (ii)
a marked redistribution of AQP2 water channels in the
FIG. 3. Electron micrograph of ultrathin Lowicryl section of inner medullary collecting duct principal cells from CHF rat. Abundant AQP2
immunogold labeling is associated with the apical plasma membrane and only modest labeling is seen of intracellular vesicles (arrowhead). M,
mitochondria. (375,000.)
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principal cells such that most of the channels are present in the
apical plasma membrane. Both modes of dysregulation would
be expected to be associated with enhancement of collecting
duct water permeability and increased water absorption from
the collecting duct. Thus, these results provide an explanation
for excess free-water retention in severe CHF and for the
development of hyponatremia. Both modes of dysregulation
are most likely attributable to chronically increased circulating
levels of vasopressin.
Physiological studies have demonstrated two general mech-
anisms by which vasopressin increases water permeability in
the renal collecting duct. The first, short-term regulation, is
manifest within a few minutes after a rise in circulating
vasopressin levels and is due to trafficking of AQP2 water
channel vesicles to the apical plasma membrane (7). The
second, long-term regulation, is manifest only after many
hours or days of increased vasopressin levels and is due to an
increase in the abundance of the AQP2 protein in collecting
duct cells (6, 11, 19). The latter mode of regulation is also
associated with a rise in AQP2 mRNA levels and is most likely
due to increased transcription of the AQP2 gene (reviewed in
ref. 5). The results of the present study make it clear that the
water retention associated with severe CHF is due, at least in
part, to marked augmentation of both the short- and long-term
regulatory processes.
Defects in the long-term regulation of AQP2 expression
have previously been implicated in a wide range of water
balance disorders including central diabetes insipidus (11, 29)
and acquired diabetes insipidus due to lithium intoxication
(12), to prolonged hypokalemia (13), to ureteral obstruction
(14), and to purine amino nucleoside toxicity (30). Recently, a
study of CCl4-induced hepatic cirrhosis with water retention by
Saito and coworkers (15) has extended this list to include also
disorders associated with free-water retention and hyponatre-
mia. The present study demonstrated that in rats with CHF, a
condition known clinically to be associated with severe alter-
ation in water balance, AQP2 expression is significantly in-
creased suggesting a role in the development of free water
retention. This conclusion is supported by the evidence pre-
sented here that AQP2 expression was only increased in severe
CHF with reduced plasma sodium concentrations, but was not
increased in rats with mild heart failure and no decrease in
plasma sodium concentrations. Recently, similar observations
demonstrating increased AQP2 levels in kidneys of rats with
chronic heart failure have been made in a preliminary report
(31).
Our studies are consistent with the view that the observed
reduction in plasma sodium is secondary to the increase in
AQP2 expression. This is supported by the observation that
rats with mild heart failure with LVEDP , 15 mmHg showed
no increase in AQP2 expression nor did they show any
reduction in plasma sodium concentrations (Tables 1 and 2).
The reduction in plasma sodium concentration in rats with
severe CHF can be speculated to be related to the severity of
the disease and may only occur as a terminal event.
Abundant AQP2 in Apical Plasma Membrane in CHF. A
striking finding was the extraordinary redistribution of AQP2
within the collecting duct principal cells of rats with severe
CHF. Both immunocytochemistry and immunoelectron mi-
croscopy demonstrated that AQP2 was almost exclusively
localized to the plasma membranes whereas AQP2 labeling
was reduced in cytoplasmic vesicles. This labeling pattern in
the CHF rat kidneys is almost identical to the labeling pattern
observed in rats treated with dDAVP (1-desamino-8-D-
arginine-vasopressin) for 30 min (8). Furthermore, the pattern
is similar to the one found in Brattleboro rat kidneys after
vasopressin treatment (9, 11). Since vasopressin acutely regu-
lates the apical plasma membrane water permeability by
shuttling of AQP2 from an intracellular compartment in
vesicles to the apical plasma membrane (7–10), the marked
changes in the subcellular distribution in kidneys of CHF rats
is fully consistent with a significant effect of vasopressin,
known to be elevated in CHF (1). The findings that AQP2 is
very efficiently targeted to the plasma membrane in rats with
CHF strongly support the view that enhanced AQP2 shuttling
to the apical plasma membrane contributes to the free water
retention seen in CHF. Thus, excessive activation of the
short-term mechanism of AQP2 regulation in CHF augments
the effect of over-expression of AQP2 protein.
Signaling Pathways Potentially Involved in Modulating
AQP2 Expression and Targeting in CHF. Several studies have
demonstrated a highly significant increase in vasopressin levels
in CHF both in patients and in experimental models of CHF
(1, 32–35). Diminished circulatory perfusion due to CHF is
believed to activate arterial baroreceptors residing in the
carotid sinus and aortic arch. This may produce activation of
the sympathetic nervous system, renin–angiotensin system,
and the nonosmotic release of AVP (arginine-vasopressin) (1).
Because vasopressin treatment induces the expression of
AQP2 (11), it is very likely that the increased AQP2 expression
in the CHF rats (Table 2) is a direct result of increased
FIG. 4. (A and B) Immunoblots of total kidney membrane fractions
(20 mgylane) from sham-operated control animals and CHF animals.
In A, the immunoblot was reacted with anti-AQP1 serum and the
29-kDa AQP1 band is shown. In B, the immunoblot was reacted with
affinity purified anti-AQP3 and the 27-kDa AQP3 band is shown. (C)
Densitometry of AQP1 expression in sham-operated controls (n5 14)
and in rats with CHF (n5 12). No change in AQP1 expression is seen.
(D) Densitometry of AQP3 expression in sham-operated controls (n5
14) and in rats with CHF (n 5 12). A modest decrease in AQP3
expression is seen.
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vasopressin levels. However, contribution of other regulatory
factors cannot be totally excluded at this stage.
Increase in AQP2 but Not in AQP1 or AQP3 Expression in
CHF. The increase in AQP2 expression appears to be rather
selective. This was documented by using two additional mem-
brane protein markers. AQP1 is very abundant in proximal
tubules and descending thin limbs, and this water channel has
been shown not to be regulated by vasopressin, by thirsting, or
by water loading (19). Consistent with this, no change in AQP1
expression was observed in rats with CHF (Table 2). More-
over, we tested for possible change in AQP3 expression
(26–28), which is abundant in the basolateral plasma mem-
brane of collecting duct principal cells (21). There was no
increase in AQP3 expression in CHF, rather a slight decrease
in expression (Table 2). Thus, the absence of an increase in
AQP1 and AQP3 expression strongly supports a selective
increase in AQP2 expression. Selective change in AQP2
expression without change in AQP3 expression has also been
reported in rats fed a low-protein diet and which have a
concentrating defect (36). Like AQP2, AQP3 expression ap-
pears to be regulated by long-term mechanisms (19, 21).
Further studies will be required to determine the basis at a
transcription level of long-term regulation of AQP2 (and of
AQP3) in states of water retention or polyuria.
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